Abstract
Metastatic breast cancer (MBC) is quite sensitive to chemotherapy, with patients often benefiting from multiple lines of treatment. Continuation of chemotherapy until disease progression, if tolerable, prolongs disease control and improves patient outcomes. Compared to combination regimens, sequential single-agent chemotherapy provides similar efficacy and improved tolerability and may represent the preferred option for most patients. Numerous agents are available, but there are few data to advise optimal sequencing. Oral chemotherapeutic agents, including capecitabine and vinorelbine, have demonstrated significant efficacy in patients with MBC. These drugs prolong disease control with good tolerability, especially when used as single agents. In addition, oral chemotherapy reduces the time and cost associated with treatment and usually is preferred by patients if compared with intravenous delivery. Metronomic administration of oral chemotherapy also represents a promising therapeutic approach for select patients with MBC, inhibiting tumor progression through multiple mechanisms of action. Ongoing clinical trials are exploring metronomic regimens as a strategy to prolong disease control with favorable tolerability. Key data on the role for oral chemotherapy in the therapeutic landscape for MBC will be reviewed and accompanied by expert perspectives on important considerations for the integration of oral chemotherapeutic agents into the treatment of patients with MBC.
| Original language | English |
|---|---|
| Pages (from-to) | S1-S10 |
| Journal | Cancer Treatment Communications |
| Volume | 6 |
| DOIs | |
| Publication status | Published - Jun 1 2016 |
Fingerprint
Keywords
- Breast cancer
- Capecitabine
- Chemotherapy
- Metastatic
- Metronomic drug administration
- Oral drug administration
- Patient selection
- Quality of life
- Safety
- Vinorelbine
ASJC Scopus subject areas
- Oncology
Cite this
Oral chemotherapy in advanced breast cancer : expert perspectives on its role in clinical practice. / Cardoso, Fatima; Colleoni, Marco; Di Leo, Angelo; Francia, Giulio; Gennari, Alessandra; Gligorov, Joseph; Llombart, Antonio.
In: Cancer Treatment Communications, Vol. 6, 01.06.2016, p. S1-S10.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Oral chemotherapy in advanced breast cancer
T2 - expert perspectives on its role in clinical practice
AU - Cardoso, Fatima
AU - Colleoni, Marco
AU - Di Leo, Angelo
AU - Francia, Giulio
AU - Gennari, Alessandra
AU - Gligorov, Joseph
AU - Llombart, Antonio
PY - 2016/6/1
Y1 - 2016/6/1
N2 - Metastatic breast cancer (MBC) is quite sensitive to chemotherapy, with patients often benefiting from multiple lines of treatment. Continuation of chemotherapy until disease progression, if tolerable, prolongs disease control and improves patient outcomes. Compared to combination regimens, sequential single-agent chemotherapy provides similar efficacy and improved tolerability and may represent the preferred option for most patients. Numerous agents are available, but there are few data to advise optimal sequencing. Oral chemotherapeutic agents, including capecitabine and vinorelbine, have demonstrated significant efficacy in patients with MBC. These drugs prolong disease control with good tolerability, especially when used as single agents. In addition, oral chemotherapy reduces the time and cost associated with treatment and usually is preferred by patients if compared with intravenous delivery. Metronomic administration of oral chemotherapy also represents a promising therapeutic approach for select patients with MBC, inhibiting tumor progression through multiple mechanisms of action. Ongoing clinical trials are exploring metronomic regimens as a strategy to prolong disease control with favorable tolerability. Key data on the role for oral chemotherapy in the therapeutic landscape for MBC will be reviewed and accompanied by expert perspectives on important considerations for the integration of oral chemotherapeutic agents into the treatment of patients with MBC.
AB - Metastatic breast cancer (MBC) is quite sensitive to chemotherapy, with patients often benefiting from multiple lines of treatment. Continuation of chemotherapy until disease progression, if tolerable, prolongs disease control and improves patient outcomes. Compared to combination regimens, sequential single-agent chemotherapy provides similar efficacy and improved tolerability and may represent the preferred option for most patients. Numerous agents are available, but there are few data to advise optimal sequencing. Oral chemotherapeutic agents, including capecitabine and vinorelbine, have demonstrated significant efficacy in patients with MBC. These drugs prolong disease control with good tolerability, especially when used as single agents. In addition, oral chemotherapy reduces the time and cost associated with treatment and usually is preferred by patients if compared with intravenous delivery. Metronomic administration of oral chemotherapy also represents a promising therapeutic approach for select patients with MBC, inhibiting tumor progression through multiple mechanisms of action. Ongoing clinical trials are exploring metronomic regimens as a strategy to prolong disease control with favorable tolerability. Key data on the role for oral chemotherapy in the therapeutic landscape for MBC will be reviewed and accompanied by expert perspectives on important considerations for the integration of oral chemotherapeutic agents into the treatment of patients with MBC.
KW - Breast cancer
KW - Capecitabine
KW - Chemotherapy
KW - Metastatic
KW - Metronomic drug administration
KW - Oral drug administration
KW - Patient selection
KW - Quality of life
KW - Safety
KW - Vinorelbine
UR - http://www.scopus.com/inward/record.url?scp=84976532841&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84976532841&partnerID=8YFLogxK
U2 - 10.1016/S2213-0896(16)06001-1
DO - 10.1016/S2213-0896(16)06001-1
M3 - Article
AN - SCOPUS:84976532841
VL - 6
SP - S1-S10
JO - Cancer Treatment Communications
JF - Cancer Treatment Communications
SN - 2213-0896
ER -